Effect of Semaglutide 0.25mg on glycemic controls in type2 diabetes patients compared with dulaglutide 0.75mg. - Effect of Semaglutide 0.25mg on glycemic controls in type2 diabetes patients compared with dulaglutide 0.75mg.

开始日期2020-11-06

申办/合作机构-

100 项与司美格鲁肽口服锭剂(水星生医) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽口服锭剂(水星生医) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽口服锭剂(水星生医) 相关的专利（医药）

登录后查看更多信息

304

项与司美格鲁肽口服锭剂(水星生医) 相关的文献（医药）

2025-10-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data

Article

作者: Esposito, Katherine ; Capuano, Annalisa ; Caruso, Paola ; Mascolo, Annamaria ; Ruggiero, Rosanna ; Longo, Miriam ; D'Amato, Rossana ; Di Nuzzo, Michela ; Rafaniello, Concetta ; Maiorino, Maria Ida ; Laino, Ludovica Vittoria

BACKGROUND:

In recent years, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), as liraglutide and semaglutide, for weight management has significantly risen. Even if these medications are effective, some concerns remain about their safety profiles, particularly regarding long-term adverse events (AEs). This study provides an evaluation of the safety profiles of liraglutide and semaglutide in a real-world setting.

METHODS:

A retrospective case-non-case study was conducted using data from the EudraVigilance database. All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed. Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.

RESULTS:

A total of 27,639 cases were identified. Most cases occurred in female patients aged 18-64 years. Most reported AEs were not-serious. Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list. Two events were related to gallbladder tumors. Disproportionality analysis revealed that liraglutide was associated with a higher reporting frequency of pancreatitis, gallbladder disorders, and thyroid tumors, while semaglutide showed a greater likelihood of vomiting and abdominal pain. No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.

CONCLUSIONS:

Liraglutide and semaglutide showed distinct safety profiles when used for weight management. These findings highlight the importance of considering individual patient profiles and potential risks when prescribing these medications for weight management. Further real-world studies are needed to explore long-term safety and to clarify the potential association between GLP-1 RAs and malignancies.

2025-09-01·Obesity Pillars

Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system

Article

作者: Rizo, Ivania ; Fantasia, Kathryn L ; Campos, Alejandro

Background:

Obesity is a highly prevalent, chronic, and treatable disease that disproportionately impacts some minoritized populations who seek care in safety-net settings. Given that primary care providers (PCPs) often serve as the initial point of contact for patients, we aimed to assess their knowledge, attitudes, and practices related to management of obesity.

Methods:

This was a cross-sectional study conducted to assess knowledge, attitudes, and practices on obesity management through an anonymous, electronic survey among trained (MD/DO and NP) and in-training (residents) primary care providers (PCPs) in the Departments of Internal Medicine and Family Medicine within an urban safety-net healthcare system.

Results:

Among 350 sampled, 96 PCPs completed the survey (27 % response rate). Participants were predominantly (60.4 %) Internal Medicine trainees. The majority of PCPs accurately identified common weight-related comorbidities and improvement of these with >10 % weight loss. Only 25 % of PCPs correctly identified both body mass index (BMI) criteria for anti-obesity medication (AOM) prescription and only 9.1 % identified both BMI criteria for bariatric surgery. Nearly two-thirds (64 %) of PCPs reported prescribing AOMs, with greater comfort in using glucagon like peptide-1 receptor agonist (GLP-1 RA) injectable agents (semaglutide and liraglutide) than with older oral AOMs (phentermine, phentermine-topiramate, and naltrexone-bupropion). Knowledge about side effects and insurance coverage were reported as influencing AOM prescription. Time constraints and lack of training and/or knowledge were identified as barriers in obesity management by more than 50 % of PCPs.

Conclusions:

Our study highlights gaps in obesity-related knowledge and practice among PCPs, emphasizing the need for enhanced training, clinical support, and policy reforms to improve obesity management and patient outcomes.

2025-09-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials

Review

作者: Parmar, Mayur S ; Choudhari, Jashkumar ; Miranda, Sarah ; Chauhan, Nehabahen

Semaglutide, a glucagon-like peptide-1 receptor agonist, is known for weight reduction and glycemic control and is approved to lower major cardiovascular event risk in adults with overweight or obesity. While individual trials have explored its effects on lipid profiles in non-diabetic adults with overweight or obesity, a comprehensive pooled analysis has been lacking. Dyslipidemia, a key modifiable cardiovascular risk factor, prompted this meta-analysis-the first to evaluate semaglutide 2.4 mg's impact on total cholesterol, low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides in this population. A systematic search identified four randomized controlled trials evaluating semaglutide 2.4 mg over 68 weeks or more in non-diabetic adults with overweight or obesity. A random-effects meta-analysis was conducted to calculate pooled mean differences (MDs) and 95 % confidence intervals (CIs) for lipid parameters, taking into account study heterogeneity. Semaglutide significantly reduced total cholesterol (MD: 6.39 mg/dL, 95 % CI: 9.25 to -3.53, p < 0.01), LDL-C (MD: 6.01 mg/dL, 95 % CI: 10.17 to -1.85, p < 0.01), VLDL-C (MD: 10.67 mg/dL, 95 % CI: 17.79 to -3.54, p < 0.01), and triglycerides (MD: 14.75 mg/dL, 95 % CI: 21.30 to -8.19, p < 0.01), while slightly increasing HDL-C (MD: +1.82 mg/dL, 95 % CI: 0.90 to 2.74, p < 0.01). Semaglutide 2.4 mg weekly improves lipid profiles in non-diabetic adults with overweight or obesity, suggesting metabolic benefits beyond weight loss. These findings highlight a potential mechanism for semaglutide cardiovascular risk reduction, given the link between improved lipid profiles and lower cardiovascular risk. TRIAL REGISTRATION: PROSPERO registration: CRD42025100858.

项与司美格鲁肽口服锭剂(水星生医) 相关的新闻（医药）

2025-07-30

·ETPharma

CDMO biz drive Jubilant Pharmova Q1 FY26 revenue to ₹1900 cr, net profit leaps 48%

New Delhi: Jubilant Pharmova ended the first quarter of fiscal year 2025-26 with a revenue of ₹1,901 crore, up by 10 per cent from the previous fiscal same quarter. With profit margin recording a sharp increase of 140 basis points, the company’s normalized PAT for the quarter stood at ₹103 crore, reflecting a jump of 48 per cent against the previous fiscal. For the period Reported PAT stood at ₹482 crore, up from ₹396 crore due to one-time net exceptional income. During the April-June quarter Jubilant Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBIDTA) stood at ₹302 crore at an EBIDTA margin of 15.8 per cent. The quarter performance is attributed with the a “strong customer traction in the company’s CDMO Sterile Injectable business” which reported a revenue of ₹370 crore, up by 14 per cent on YoY with a EBITDA of ₹62 crore. Several global drugmakers have placed orders for their generic versions ahead of semaglutide’s patent expiry slated early next year. Jubilant's radiopharmaceutical segment–US specific operations—posted a revenue of ₹271 crore with a marginal increase of 3 per cent on YoY basis while radiopharmacy business clocked ₹598 crore. “The dosing for Phase 2 clinical trial for MIBG is complete and we are preparing data package to be submitted to FDA by H2’FY26 and we are on track to introduce multiple new products in the PET and SPECT imaging from FY27 to FY29,” the company said in a release. Meanwhile, the proposed investment of $50 million (~₹425 crore) in PET radiopharmacy network is underway, it added. According to the company the proposed investment will expound its PET radiopharmacy network to nine sites, and will position it as the second largest radiopharmacy network in the US. Revenue from the generics business stood at ₹172 crore with an EBITDA of ₹12 crore. Sharing an update over its property novel drug pipeline the company said, it is " actively enrolling patients and progressing in line with its expectations.” Jubilant novel pipeline includes JBI -802 for Essential Thrombocythemia (ET), other Myeloproliferative Neoplasms (MPN) and JBI -778, a Phase 1 trail candidate for non-small cell lung cancer (NSCLC) and high grade Glioma. On its future outlook the company stated, “we are ramping up exports to the US markets in a meaningful and gradual manner and plan to launch 6 to 8 products per annum in our US and non-US international markets.” By Online Bureau ,

临床1期财报

2025-07-17

·PRNewswire

Weight Loss Drugs Like Ozempic May Help Prevent Stroke and Reduce Brain Injury-Related Complications, Studies Show

NASHVILLE, Tenn., July 17, 2025 /PRNewswire/ -- Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether. These medications, which lower blood sugar and often cause weight loss, are commonly prescribed for type 2 diabetes and obesity and include drugs like semaglutide (Ozempic). In the first study, "The Impact of Semaglutide (Ozempic) on Mortality and Survival in Patients with Acute Ischemic Stroke: A Nationwide and Institutional Retrospective Analysis," researchers at the University of Wisconsin–Madison used patient data from both the university's medical center and a global health collaborative to see whether patients on Ozempic who experienced strokes had better outcomes than patients not taking Ozempic. The global dataset included 2,021,704 patients who had experienced stroke, 43,338 of whom were also on Ozempic, and the University of Wisconsin dataset included 13,510 people who had experienced stroke, 190 of whom used Ozempic. Death from stroke was lower for Ozempic users across both cohorts. In the global dataset, 5.26% of Ozempic users initially died from their strokes compared to 21.61% of non-users, and Ozempic users also had a 77.5% chance of surviving their strokes long term compared to 30.95% of non-Ozempic users. The university cohort showed similar results, with 5.26% of Ozempic users dying from stroke versus 26.57% of patients not using Ozempic. In the second study, also from the University of Wisconsin–Madison, "Association between Ozempic Use and Stroke Risk: A Nationwide Emergency Department Analysis," researchers examined a large nationwide sample of emergency department records for people who experienced stroke and people who were likely using Ozempic. They found associations between potential Ozempic users and significantly reduced odds of stroke. The research team suggests taking this research further to evaluate data directly from pharmacies to be even more precise about the relationship between Ozempic and stroke prevention. The third study, "Impact Of GLP-1 Agonists on Stroke, SAH, and ICH: A Propensity-matched Multi-institutional Cohort Study," was presented by researchers from the University of Texas Medical Branch in Galveston. They investigated whether GLP-1 inhibitors could improve patient outcomes after brain hemorrhages (both spontaneous bleeds and those due to brain aneurysm rupture) and stroke. The team reviewed patient records from 6 months and 12 months after each brain hemorrhage and 1 year and 2 years after each stroke, finding that GLP-1 inhibitor use was connected to a reduced risk of cognitive side effects, seizures, future brain hemorrhage and death after brain hemorrhage and stroke. According to Ahmed Elbayomy, MD, a research fellow and data scientist in the Department of Neurological Surgery at the University of Wisconsin–Madison and primary author of two of these studies, these results are very promising. "More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding." "This research could introduce a new perspective to the discussion of preventing and mitigating the devastating effects of stroke and related brain injuries," added Matias Costa, MD, from the Neurosurgery Department at the University of Texas Medical Branch and author of the third study. To receive a copy of these abstracts or to speak with the study authors, please contact Camille Jewell at [email protected] or call 202-248-5460. About the Society of NeuroInterventional Surgery The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head and neck. Visit and follow us on X (@SNISinfo) Facebook (@SNISOnline), LinkedIn (@Society of NeuroInterventional Surgery), Instagram (@SNIS_info) and Bluesky (@snisinfo.bsky.social). SOURCE Society of NeuroInterventional Surgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果

2025-07-07

·国际糖尿病idiabetes

代谢心前沿 | 都健教授：聚焦SELECT研究：司美格鲁肽对多重心血管代谢指标改善的效应分析

点击“蓝字”关注我们编者按减重干预被证实可显著降低主要不良心血管事件（MACE）的发生率，但多数传统减重药物因心血管安全性争议而临床应用受限。胰高糖素样肽-1受体激动剂（GLP-1RA）司美格鲁肽2.4mg因其出色的心血管保护作用成为研究热点。SELECT研究是全球首个针对非2型糖尿病（T2DM）超重/肥胖合并CVD人群的心血管结局试验（CVOT），证实司美格鲁肽2.4mg可使MACE风险显著降低20%，为GLP-1RA类药物在心血管二级预防中的临床价值提供了高级别循证医学证据。本文将基于SELECT研究的核心发现，系统解析司美格鲁肽对心血管代谢指标的多维度改善效应。同时，《国际糖尿病》特别邀请到中国医科大学附属第四医院都健教授围绕研究结论进行深度点评，探讨该药物在肥胖症合并CVD管理中的潜在临床应用前景。都健教授中国医科大学附属第四医院内分泌代谢学博士博士后中国医科大学附属第四医院教授主任医师博士生导师辽宁名医《国际糖尿病》从流行病学与病理生理学视角出发，肥胖/超重对于CVD的发生有怎样的影响？近期该领域有哪些重要研究成果值得关注？都健教授：在我国，肥胖症已成为位列第六的导致死亡和残疾的主要危险因素[1]，在肥胖人群中，约2/3的死亡事件归因于CVD[2]，其病理机制涉及代谢稳态失衡、慢性低度炎症、血管内皮功能障碍及心脏重构等多重病理生理通路[3]，这些机制通过协同作用加速动脉粥样硬化进程，诱发高血压、心力衰竭等严重心血管事件。减重是肥胖症干预的关键性措施，可使MACE发生率降低15%~20%，全因死亡率显著下降11.8%[1,3]。然而，大多数减重药物因引发严重的心血管不良事件而未能广泛应用。01司美格鲁肽2.4mg减重效能与多维度心血管保护效应：STEP系列研究证据STEP系列研究表明，对于非T2DM的超重/肥胖症患者，使用司美格鲁肽2.4mg可显著降低体重15%~17%，超过70%的患者体重减轻幅度至少达10%，且其减重效果至少可维持2年[4-6]。STEP系列研究同时也为司美格鲁肽2.4mg的心血管保护作用提供了证据：在血流动力学指标方面，STEP 6研究显示司美格鲁肽2.4mg组的收缩压显著降低约11mmHg[7]；在脂代谢调节方面，STEP 7研究中试验组患者的总胆固醇和甘油三酯分别降低了5.2%和28%[8]；针对射血分数保留型心衰（HFpEF），STEP HFpEF研究的事后分析结果表明，无论患者基线肥胖分级如何，司美格鲁肽2.4mg均可显著改善堪萨斯城心肌病问卷临床总结评分（KCCQ - CSS），表现为减轻HFpEF患者的心衰症状严重程度、改善运动功能以及降低全身性炎症水平[9]。02心血管保护效应的异质性探索与临床转化：从SUSTAIN 6研究到SELECT研究SUSTAIN6研究表明，在T2DM患者中，司美格鲁肽0.5mg/1.0mg剂量组MACE风险显著降低26%[10]。SELECT研究作为首个针对非T2DM人群的CVOT，证实司美格鲁肽2.4mg可使超重/肥胖合并CVD患者MACE风险降低20%（HR 0.80，95%CI：0.72~0.90），且该获益独立于体重减轻幅度[11]。该发现不仅完善了GLP-1RA类药物的循证证据链，更确立了体重管理在二级预防中的独立临床价值。《国际糖尿病》如您前述，SELECT研究被认为是全球首个证实减重药物具有心血管获益的CVOT，可否请您详细介绍该研究中司美格鲁肽在改善心血管代谢指标方面的具体表现，以及这些改善对降低CVD风险所具有的重要意义？都健教授：SELECT 研究是一项国际性的随机、双盲、安慰剂对照临床试验，旨在评估司美格鲁肽2.4 mg对超重/肥胖且合CVD的非T2DM患者MACE发生风险的影响。该研究入组标准为年龄≥45岁、BMI≥27 kg/㎡、合并心血管疾病且无糖尿病病史，入组者按照1:1的比例随机分配至安慰剂组和司美格鲁肽2.4 mg组。主要终点为心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点；次要终点包括心血管死亡风险、心衰复合终点事件风险以及全因死亡风险[11]。01SELECT 研究关键结果：司美格鲁肽2.4 mg可降低入组患者MACE风险达20%研究共纳入17,604例患者，最长随访时间长达5年。与安慰剂组相比，司美格鲁肽2.4 mg可显著降低患者的 MACE（心血管死亡、非致死性心肌梗死及非致死性卒中）风险达20%（HR=0.80，P<0.001）。在确证性次要终点方面，与安慰剂组相比，司美格鲁肽2.4 mg组的心血管死亡风险降低15%，心衰复合终点事件风险降低18%，全因死亡风险降低19%。司美格鲁肽2.4 mg显著降低入组患者的MACE风险 A.主要心血管复合终点的累积发生率;B. 心血管原因导致的死亡率；C. 心竭复合终点发生率；D.全因死亡率02心血管代谢指标评估：司美格鲁肽2.4 mg多维度发挥心血管保护作用1、腰围：司美格鲁肽2.4 mg组的体重减轻效果可维持4年之久。在第208周时，司美格鲁肽2.4 mg组的体重平均降幅约为10.2%，腰围平均减少约7.7 cm；而安慰剂组患者的体重平均降幅仅为1.5%，腰围平均减少1.3 cm。2、血压：在104周的随访中，与安慰剂组相比，司美格鲁肽2.4 mg组的收缩压和舒张压分别降低了3.3 mmHg和0.6 mmHg。进一步按基线有无高血压史或血压分级进行分层，结果显示，无论基线血压分级如何，司美格鲁肽2.4 mg均显著降低了收缩压数值。3、炎症：积极控制炎症反应是降低动脉粥样硬化及心血管风险的重要措施。SELECT研究的次要分析评估了超敏C反应蛋白（hsCRP）水平与体重及MACE结局的相关性。结果显示，与安慰剂组相比，司美格鲁肽2.4 mg显著降低了hsCRP水平达37.8%，所有亚组中体重下降幅度与hsCRP降幅均呈正相关；即使在体重下降<5%的受试者中，司美格鲁肽2.4 mg也能降低其hsCRP水平。司美格鲁肽2.4 mg在不同炎症水平的患者中均表现出心血管保护作用，无论患者的初始炎症状态如何，均能通过调控炎症反应降低心血管事件的发生风险[12]。4、血糖：亚组分析结果显示，无论患者基线糖化血红蛋白（HbA1c）水平如何，以及是否合并心衰病史，司美格鲁肽2.4 mg均能显著降低患者的MACE风险[13]。SELECT研究还发现，长期使用司美格鲁肽2.4 mg可延缓糖尿病的进展。在156周时，司美格鲁肽组69.5%的受试者血糖恢复正常，进展为糖尿病的风险较安慰剂组降低73%[14]。5、早期临床获益：2025年欧洲肥胖症大会（ECO）上公布的SELECT研究二次分析，着重评估了司美格鲁肽2.4 mg在超重或肥胖合并心血管疾病成人患者中的早期临床获益情况。结果显示，在随机分组后的6个月治疗期内，与安慰剂组相比，司美格鲁肽2.4 mg组MACE风险降低41%，心血管死亡风险降低53%，非致死性心梗风险降低43%，且能在短时间内降低MACE风险[15]。总之，以上研究数据构建了司美格鲁肽2.4 mg在心血管代谢方面的多维获益证据链，其作用机制可能涉及体重调控、血流动力学优化、炎症抑制及糖稳态调节等多重通路，为超重/肥胖CVD患者的综合管理提供了新思路。《国际糖尿病》除疗效外，药物安全性也是医患双方高度关注的核心要点。请您继续基于SELECT研究，探讨司美格鲁肽2.4 mg在改善心血管多重代谢指标过程中的安全性情况？都健教授：安全性问题始终是减重药物研发的核心挑战。纵观全球药物研发史，多款肥胖症治疗药物因严重不良反应（如心血管毒性风险增加、中枢神经系统不可逆损伤等）触发撤市事件[16]。此类安全性事件促使监管机构对新型减重药物的审批标准显著趋严 [17]，标志着该领域研发已进入“安全性优先”的新阶段。01真金不怕火炼：司美格鲁肽2.4 mg的安全性特征已在多项研究中得到系统性验证STEP系列临床试验的结果显示，司美格鲁肽2.4 mg组的AE发生率与安慰剂组无显著统计学差异，主要表现为轻至中度的胃肠道事件（如恶心、腹泻），且这些事件多发生于剂量递增期。这一结果与GLP-1RA类药物已知的安全性谱一致，提示其胃肠道不良反应具有剂量依赖性及可逆性特征。02SELECT研究深度评估：司美格鲁肽2.4 mg的安全性特征显著优于对照组2024心血管安全评价大会（CSE）公布的SELECT研究数据显示，司美格鲁肽2.4 mg组严重不良事件（SAE）发生率显著低于安慰剂组（33.4% vs. 36.4%，P<0.001），且关键安全性终点分析呈现以下特征：1、特异性SAE风险：治疗组与安慰剂组在急性胰腺炎（0.3% vs. 0.4%，P=0.21）、恶性肿瘤（4.2% vs. 4.5%，P=0.38）及自杀倾向相关事件（0.1% vs. 0.2%，P=0.15）的发生率上均无显著统计学差异[19]。2、停药事件分析：司美格鲁肽2.4 mg治疗组因胃肠道AE导致的停药率为6.8%，稍高于安慰剂组（3.2%），但其中仅1.7%为持续性停药，提示可通过剂量调整或对症处理缓解。3、代谢相关性风险：胆囊疾病发生率轻微升高（2.8% vs. 2.3%，P=0.013），但未达临床警戒阈值，且与减重速度呈非剂量依赖性。综上所述，司美格鲁肽2.4 mg的安全性特征已得到充分验证，SELECT研究数据则进一步坐实了司美格鲁肽2.4 mg在超重/肥胖合并CVD人群中具有更显著的安全性优势，为临床用药提供了高质量循证依据。《国际糖尿病》在现有研究的基础上，未来关于司美格鲁肽在改善多重代谢指标方面的研究存在哪些局限性？您认为哪些潜在研究领域值得进一步深入探索？都健教授：01现存研究的局限性1、长期安全性评估的时效性缺陷：现有临床试验随访周期较短，尚无法充分验证司美格鲁肽2.4 mg超长期应用对心血管稳态、肿瘤发生风险及代谢代偿效应的影响[20]。其短期代谢指标改善的持续性仍需延长观察周期以确认剂量-效应关系。2、人群多样性的地理与遗传学局限：当前用药证据主要源于欧美人群，对亚洲等族群在药物代谢动力学、脂肪分布模式及共病特征的特异性响应缺乏系统研究[11,19]，可能导致临床指南的地域适应性受限。3、多靶点作用机制的分子生物学缺口：现有研究关于司美格鲁肽2.4 mg如何同时影响血糖、体重、脂质、血压等多项指标的分子机制的深入探讨尚显不足，这限制了对其多重作用深层次机制的理解[21]。4、个体化治疗策略的循证空白：对于不同遗传背景、不同基础代谢状态或伴随疾病患者的个体化反应差异研究尚不充分，难以制定个性化的治疗方案。5、联合治疗协同效应的机制缺位：现有研究集中于单药治疗，未系统评估司美格鲁肽2.4 mg与现有其他治疗手段或新兴疗法的协同作用。02未来研究的布局与规划1、多层次长期研究体系构建：开展大规模、多中心的长期随机对照试验，评估司美格鲁肽2.4 mg在多重代谢指标改善中的持续疗效、安全性及其对心血管结局的影响。2、分子机制的多维度解析路径：深入探讨司美格鲁肽对脂质代谢、血压调控、炎症反应、脂肪组织功能及肝脏代谢的分子机制。3、多样化人群队列研究设计，助力开发个性化诊疗策略：分析不同人群（如不同遗传背景、伴随特定疾病的患者）对司美格鲁肽2.4 mg反应的差异，推动个性化、多指标同时改善的用药方案。4、探索联合治疗策略：探究司美格鲁肽2.4 mg与其他药物或治疗手段的协同作用及其对心血管多重代谢指标的综合改善效果，以期实现更为全面的治疗方案。结语 SELECT研究证实，司美格鲁肽2.4 mg可使超重/肥胖合并CVD患者的MACE风险降低20%，且在心血管死亡、心衰及全因死亡风险上均呈现显著获益。此外，该药物在体重、血压、炎症标志物及血糖控制等方面均展现出积极的影响，且安全性优势显著，进一步支持其在心血管保护中的多维作用机制，为超重/肥胖合并CVD患者的综合管理提供了新启迪。参考文献（上下滑动可查看）[1]《肥胖症诊疗指南（2024年版）》. https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20241119/1732009390032014270.pdf[2] Afshin A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6; 377(1): 13-27[3] Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2025;32(3):184-220[4] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11): 989-1002[5] Garvey et al. Presented at the 39th Annual Meeting of The Obesity Society (-S) held at ObesityWeek, virtual meeting, November 1–5, 2021[6] Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022; 28(10): 2083-2091[7] Kadowaki T, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022; 10(3): 193-206[8] Mu Y, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024; 12(3): 184-19[9] Borlaug BA, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023 Sep;29(9):2358-2365[10] Marso SP, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844[11] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 2023, 389(24):2221-2232[12] Plutzky J, et al. Abstract accepted by the 92nd European Atherosclerosis Society (EAS)2024; 26-29 May, Lyon, France [Abstract 1584][13] Verma S, et al. Presented at the American Heart Association Annual Meeting 2024, November 16–18[14] Kahn SE, et al. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care. 2024 Aug 1;47(8):1350-1359[15] Plutzky J, et al. Presented at ECO 2025, Malaga, Spain, 11–14 May 2025[16] Timo D Müller.et al. Nat Rev Drug Discov. 2022 Mar;21(3):201-223.[17] Hiatt WR, et al. JAMA. 2012 Sep 19;308(11):1099-100[18] Bergmann NC, et al. Diabetes Obes Metab. 2023;25:18-35[19] Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024 Jul;30(7):2049-2057[20] Deanfield J, et al. Obes Facts. 2024; 17 Suppl 1: 491-492.[21] https://mp.weixin.qq.com/s/p0dE5wmSz8NGdyuVq_hZqQ.声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果临床研究

100 项与司美格鲁肽口服锭剂(水星生医) 相关的药物交易

登录后查看更多信息